Quizartinib
Sign in to save this workspacePrimary targets: FLT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.737
CATDS
0.038
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Quizartinib. Strongest target: FLT3 at 97.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FLT3 | 97.9% | 2.1% |
| 2 | C_KIT | 97.3% | 2.7% |
| 3 | PDGFRB | 89.0% | 11.0% |
| 4 | FMS | 83.7% | 16.3% |
| 5 | RET | 79.5% | 20.5% |
| 6 | MUSK | 79.2% | 20.8% |
| 7 | PDGFRA | 69.8% | 30.3% |
| 8 | TRKB | 57.6% | 42.4% |
| 9 | TRKC | 53.9% | 46.1% |
| 10 | HIPK4 | 53.1% | 46.9% |
| 11 | RIPK4 | 51.4% | 48.6% |
| 12 | DDR1 | 48.2% | 51.8% |
| 13 | ERK7_MAPK15 | 44.3% | 55.7% |
| 14 | KHS_MAP4K5 | 41.4% | 58.6% |
| 15 | TRKA | 39.4% | 60.6% |
| 16 | DDR2 | 38.5% | 61.5% |
| 17 | FLT4_VEGFR3 | 36.3% | 63.7% |
| 18 | CAMKK1 | 34.7% | 65.3% |
| 19 | HGK_MAP4K4 | 33.3% | 66.7% |
| 20 | MYLK3 | 24.5% | 75.5% |
Selectivity landscape
Where Quizartinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Quizartinib.
Atlas insights for Quizartinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target10%
Off-target90%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 577.29 | |
| ALLOGRAFT_REJECTION | 1593.55 | |
| ANDROGEN_RESPONSE | 461.67 | |
| ANGIOGENESIS | 419.60 | |
| APICAL_JUNCTION | 2544.76 | |
| APICAL_SURFACE | 232.13 | |
| APOPTOSIS | 2032.49 | |
| BILE_ACID_METABOLISM | 348.87 | |
| CHOLESTEROL_HOMEOSTASIS | 343.76 | |
| COAGULATION | 209.22 | |
| COMPLEMENT | 960.61 | |
| DNA_REPAIR | 480.72 | |
| E2F_TARGETS | 1571.46 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 521.71 | |
| ESTROGEN_RESPONSE_EARLY | 908.23 | |
| ESTROGEN_RESPONSE_LATE | 864.68 | |
| FATTY_ACID_METABOLISM | 267.40 | |
| G2M_CHECKPOINT | 1670.36 | |
| GLYCOLYSIS | 668.50 | |
| HEDGEHOG_SIGNALING | 445.08 | |
| HEME_METABOLISM | 557.43 | |
| HYPOXIA | 1089.20 | |
| IL2_STAT5_SIGNALING | 705.19 | |
| IL6_JAK_STAT3_SIGNALING | 917.09 | |
| INFLAMMATORY_RESPONSE | 661.85 | |
| INTERFERON_ALPHA_RESPONSE | 138.67 | |
| INTERFERON_GAMMA_RESPONSE | 1031.51 | |
| KRAS_SIGNALING_DN | 322.05 | |
| KRAS_SIGNALING_UP | 770.16 | |
| MITOTIC_SPINDLE | 1665.38 | |
| MTORC1_SIGNALING | 891.16 | |
| MYC_TARGETS_V1 | 744.80 | |
| MYC_TARGETS_V2 | 232.84 | |
| MYOGENESIS | 975.64 | |
| NOTCH_SIGNALING | 95.87 | |
| OXIDATIVE_PHOSPHORYLATION | 573.11 | |
| P53_PATHWAY | 808.15 | |
| PANCREAS_BETA_CELLS | 115.98 | |
| PEROXISOME | 382.93 | |
| PI3K_AKT_MTOR_SIGNALING | 2147.63 | |
| PROTEIN_SECRETION | 362.56 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 98.62 | |
| SPERMATOGENESIS | 403.08 | |
| TGF_BETA_SIGNALING | 525.63 | |
| TNFA_SIGNALING_VIA_NFKB | 940.09 | |
| UNFOLDED_PROTEIN_RESPONSE | 625.32 | |
| UV_RESPONSE_DN | 1439.66 | |
| UV_RESPONSE_UP | 752.55 | |
| WNT_BETA_CATENIN_SIGNALING | 803.24 | |
| XENOBIOTIC_METABOLISM | 435.93 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.827 |
| SRR23303752 | — | 0.817 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.815 |
| aMVAC.P_005_TURBT_S223 | — | 0.806 |
| SRR12202498 | — | 0.800 |
Annotations
Sign in to read and post annotations.
Loading…